<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01684228</url>
  </required_header>
  <id_info>
    <org_study_id>0271-10-RMB-CTIL</org_study_id>
    <nct_id>NCT01684228</nct_id>
  </id_info>
  <brief_title>Impact of Hemodialysis on Exhaled Volatile Organic Compounds in End Stage Renal Disease</brief_title>
  <official_title>Impact of Hemodialysis on Exhaled Volatile Organic Compounds in End Stage Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      End stage renal disease (ESRD) is a severe clinical state of irreversible loss of endogenous&#xD;
      kidney function, shortening life expectancy, if left untreated. In the state of ESRD, over&#xD;
      5000 uremic toxins are accumulated in the body causing dysfunction of various organ systems.&#xD;
      The survival of these patients depends on renal replacement therapies, such as hemodialysis&#xD;
      (HD), which artificially purifies the blood from toxins. The investigators assume that some&#xD;
      of the uremic toxins are also present in the patient's exhaled breath, and could be detected&#xD;
      by a non-invasive and highly sensitive test: a NA-NOSE artificial olfactory system. It is&#xD;
      based on analysis of volatile organic compounds (VOCs), a novel, non-invasive field in&#xD;
      medical diagnostics. The NA-NOSE is made from an array of nanosensors, and was developed by&#xD;
      our collaborator Dr. Hossam Haick (Chemical Engineering, Technion).&#xD;
&#xD;
      In the current study, the investigators utilize this technology to identify VOCs in the&#xD;
      exhaled breath of dialysis patients, and to characterize certain patterns of expression that&#xD;
      could potentially help in future monitoring of HD adequacy. The investigators plan to collect&#xD;
      150 breath samples from patients before and during dialysis, and from healthy subjects. All&#xD;
      participants provide a signed informed consent. Subsequently, analysis of samples will be&#xD;
      done at Dr. Haick's laboratory, using Gas-Chromatography/Mass-Spectrometry and parameters&#xD;
      extracted from each sensor response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">37</enrollment>
  <condition>End Stage Renal Disease</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      exhaled breath&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hemodialysis patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 Years and older&#xD;
&#xD;
          -  End stage renal disease receiving hemodialysis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age under 18&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Malignancy&#xD;
&#xD;
          -  Infectious diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suheir Assady, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, Rambam-Health Care Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>September 10, 2012</study_first_submitted>
  <study_first_submitted_qc>September 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2012</study_first_posted>
  <last_update_submitted>May 6, 2015</last_update_submitted>
  <last_update_submitted_qc>May 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>End stage renal disease</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>breath test</keyword>
  <keyword>volatile organic compound</keyword>
  <keyword>dialysis adequacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

